Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
30 janv. 2025 05h55 HE
|
Polyrizon Ltd.
Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative...
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
23 janv. 2025 06h40 HE
|
Polyrizon Ltd.
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the...
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
30 déc. 2024 06h25 HE
|
Polyrizon Ltd.
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative...
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
19 déc. 2024 07h22 HE
|
Polyrizon Ltd.
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative...
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
18 déc. 2024 06h25 HE
|
Polyrizon Ltd.
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production...
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
13 déc. 2024 06h25 HE
|
Polyrizon Ltd.
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative...
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
02 déc. 2024 08h02 HE
|
Polyrizon Ltd.
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production...
Polyrizon Announces Closing of $4.2 Million Initial Public Offering
30 oct. 2024 10h28 HE
|
Polyrizon Ltd.
Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device...
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
28 oct. 2024 19h02 HE
|
Polyrizon Ltd.
Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device...